Looking at the title of this blog, you might have had a question mark "?" in mind. Yes, I put it, but not in the blue oval on the picture above. 

Had a chat the other day with a person working for a medical product manufacturer. "For the marketing and sales of a medical equipment, drug and whatever it would be, you will come to a wrong point of arrival enough to get rags, once you set a wrong objective." I thought the phrase was well put. The person put this, neither a "goal" or a "company sales", but "point of arrival".

Used-to-be a nurse, the person is now working as an engineer of a particular medical equipment, "Sales people meet a doctor, and apparently they don't want me to meet the doctor just because I used to be a nurse, but by taking every chance I do my best by insisting that I want to see a doctor. Because patients' voices are, or must be, the most valuable to doctors", said the former nurse. Followed by the account was the person's sigh. "I am being in continuous trouble and headache out of so many things I cannot do, but I used to do when I was working for hospitals.

#Kobayashi Kako (小林化工) was suspended from business by getting sleeping pills mixed with fungal medicine, #Nichi 'iko (日医工) was exposed of its illegal manufacturing processes for 10 years, #TakedaPharmaceutical (武田薬品) developing and manufacturing medication for breast cancer, which was recalled of some of its particular drugs. You name it. "They all had set wrong points of arrival from the beginning", the person said.  

In another occasion but with the same topic, my doctor Dr. Tabei also complained the recalls and suspensions with his serious face expression on March 3rd (Hina-matsuri Girls Day!), saying, "the have done such that illegal process manufacturing for quite a long time. Japanese medication business will be less and less appreciated."

Looking back to history, there are so many defective products being emerged to public eyes. Say airbags, for example, in auto industry were wide-reported. Medical devices will too have serious consequences, although I do not want to weigh one against another. "The patients resort their lives with medication manufactured by the companies who manufacture them," warned Dr. Masahiro Wada, Breast Surgeon of Sano Kosei General Hospital, who in his article accused Takeda of its anticancer drug's suspension. 

(The photo shows my blood test results at Mita Hospital, taken on March 3rd, 2021. The platelet count, with blue oval, showed 96,000, which is slightly below the bar (100,000) of temozolomide (trade name: Temodar) for postoperative treatment of brain tumors. But this time is for me the final round of 5-day dose in 6 months, and I was requested by the doctor to start the final round. To be continued.)